SCYNEXIS INC

SCYNEXIS, Inc. is a biotechnology company that develops treatments for severe diseases, focusing on drug-resistant and difficult-to-treat fungal infections. The company creates therapies using its proprietary platform of triterpenoid antifungal agents known as fungerps. Its lead commercialized product is ibrexafungerp, marketed as BREXAFEMME for vaginal yeast infections and licensed to GSK. SCYNEXIS also advances clinical candidates such as SCY-247, an antifungal evaluated in oral and intravenous formulations for invasive candidiasis. Its therapies target hospitalized and immunocompromised patients treated by infectious disease specialists, oncologists, and critical care physicians at major medical centers.

The company maintains an international operational reach through licensing agreements covering regions including the United States, Greater China, and Russia. SCYNEXIS does not own or operate manufacturing, storage, or laboratory facilities, relying instead on external contract manufacturers to produce its clinical supplies and drug products. The provided text does not disclose the location of the company's corporate headquarters.

Summary of the business section of Scynexis's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of March 1, 2026, we had 18 employees, all of whom were employed on a full-time basis.”